Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence
Objective: To study the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) in real-life clinical practice.Material and methods. The observational program was conducted in 73 centers across Russia from Dec 1, 2022 to Jan 31, 2025. It was based on a retrospective analys...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2025-04-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1738 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850023520666386432 |
|---|---|
| author | P. A. Shesternya A. I. Zagrebneva O. V. Antipova Yu. V. Arbuzova I. G. Bannikova L. V. Belozertseva E. A. Bogdanova S. A. Bykova E. A. Vasilenko I. B. Vinogradova S. Yu. Davidyan O. E. Epifanova E. V. Zemerova M. V. Zlobin L. V. Ivanova N. A. Ilyina L. V. Ilyushina E. P. Klyuchnikova A. V. Makevnina E. R. Myasoutova E. E. Nakonechnaya A. B. Pavlova T. V. Plaksina A. V. Rybin T. S. Salnikova L. V. Solodovnikova A. V. Fedorova I. A. Cherencova E. V. Jakovleva S. P. Yakupova E. N. Alekseev A. M. Lila |
| author_facet | P. A. Shesternya A. I. Zagrebneva O. V. Antipova Yu. V. Arbuzova I. G. Bannikova L. V. Belozertseva E. A. Bogdanova S. A. Bykova E. A. Vasilenko I. B. Vinogradova S. Yu. Davidyan O. E. Epifanova E. V. Zemerova M. V. Zlobin L. V. Ivanova N. A. Ilyina L. V. Ilyushina E. P. Klyuchnikova A. V. Makevnina E. R. Myasoutova E. E. Nakonechnaya A. B. Pavlova T. V. Plaksina A. V. Rybin T. S. Salnikova L. V. Solodovnikova A. V. Fedorova I. A. Cherencova E. V. Jakovleva S. P. Yakupova E. N. Alekseev A. M. Lila |
| author_sort | P. A. Shesternya |
| collection | DOAJ |
| description | Objective: To study the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) in real-life clinical practice.Material and methods. The observational program was conducted in 73 centers across Russia from Dec 1, 2022 to Jan 31, 2025. It was based on a retrospective analysis of real clinical practice data. Information on patients was collected and analyzed at baseline and after 1, 6, and 12 months of treatment.Results and discussion. A total of 1,576 patients (81.7% women) with RA, aged 55.0 [44.0; 63.0] years and with RA duration of 100.0 [50.0; 156.0] months, were included in the program. After 6 and 12 months of OKZ therapy, the treatment target (remission/low activity) was achieved in 63.3% and 79.8% of patients by DAS28-CRP, and in 55.4% and 75.5% by CDAI respectively. Gender, age, seropositivity, and use of biologic disease-modifying antirheumatic drugs did not significantly affect the achievement of the treatment goal. During the observation period, a significant proportion of patients were able to discontinue glucocorticoids (GCs): 51.1% of patients received GCs initially, after 6 months, 27.6% of patients still received GCs, and after 12 months, 17.0%. During the observation, OKZ treatment was discontinued in 148 (9.5%) patients: in 50 (3.2%) patients due to insufficient efficacy, in 63 (4.0%) patients due to adverse events, and in 35 (2.2%) patients due to other reasons. Conclusion. IL-6 inhibition with OKZ is both effective and safe for achieving RA therapy goals in real-world clinical settings. |
| format | Article |
| id | doaj-art-ea115c51e7da42929d9b90950807c9ea |
| institution | DOAJ |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2025-04-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-ea115c51e7da42929d9b90950807c9ea2025-08-20T03:01:21ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2025-04-01192394910.14412/1996-7012-2025-2-39-492773Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidenceP. A. Shesternya0A. I. Zagrebneva1O. V. Antipova2Yu. V. Arbuzova3I. G. Bannikova4L. V. Belozertseva5E. A. Bogdanova6S. A. Bykova7E. A. Vasilenko8I. B. Vinogradova9S. Yu. Davidyan10O. E. Epifanova11E. V. Zemerova12M. V. Zlobin13L. V. Ivanova14N. A. Ilyina15L. V. Ilyushina16E. P. Klyuchnikova17A. V. Makevnina18E. R. Myasoutova19E. E. Nakonechnaya20A. B. Pavlova21T. V. Plaksina22A. V. Rybin23T. S. Salnikova24L. V. Solodovnikova25A. V. Fedorova26I. A. Cherencova27E. V. Jakovleva28S. P. Yakupova29E. N. Alekseev30A. M. Lila31Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of RussiaCity Clinical Hospital No.52 of Healthcare Department of MoscowIrkutsk City Clinical Hospital №1Regional Clinical HospitalSurgut District Clinical HospitalZabaykalsky Regional Clinical HospitalChelyabinsk Regional Clinical HospitalProf. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia; Regional Clinical HospitalGatchina Interregional Clinical HospitalUlyanovsk Regional Clinical HospitalNational Medical Surgical Center named after N.I. Pirogov, Ministry of Health of RussiaMedical Center “RevmaMed”Budget institution of the Khanty-Mansiysk Autonomous Okrug Ugra “District Clinical Hospital”N.A. Semashko Nizhny Novgorod Regional Clinical HospitalRepublican Clinical Diagnostic Center of Ministry of Health of the Republic of UdmurtiaResearch Institute of Fundamental and Clinical ImmunologyClinical Cardiological DispensaryProf. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia; Regional Clinical HospitalMoscow Regional Research and Clinical Institute named after M.F. VladimirskyRepublican Clinical Hospital, Ministry of Health of Republic of TatarstanClinical Cardiological Dispensary”RZhD-Medicine”N.A. Semashko Nizhny Novgorod Regional Clinical HospitalIvanovo Regional Clinical HospitalTula Regional Clinical HospitalMordovian Republican Central Clinical HospitalResearch Institute of Clinical and Experimental Lymрhology – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of SciencesRegional Clinical Hospital named after S.I. SergeevResearch Institute – Regional Clinical Hospital №1 named after Prof. S.V. Ochapovsky, Ministry of Health of Krasnodar RegionKazan State Medical University, Ministry of Health of RussiaR-PharmV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaObjective: To study the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) in real-life clinical practice.Material and methods. The observational program was conducted in 73 centers across Russia from Dec 1, 2022 to Jan 31, 2025. It was based on a retrospective analysis of real clinical practice data. Information on patients was collected and analyzed at baseline and after 1, 6, and 12 months of treatment.Results and discussion. A total of 1,576 patients (81.7% women) with RA, aged 55.0 [44.0; 63.0] years and with RA duration of 100.0 [50.0; 156.0] months, were included in the program. After 6 and 12 months of OKZ therapy, the treatment target (remission/low activity) was achieved in 63.3% and 79.8% of patients by DAS28-CRP, and in 55.4% and 75.5% by CDAI respectively. Gender, age, seropositivity, and use of biologic disease-modifying antirheumatic drugs did not significantly affect the achievement of the treatment goal. During the observation period, a significant proportion of patients were able to discontinue glucocorticoids (GCs): 51.1% of patients received GCs initially, after 6 months, 27.6% of patients still received GCs, and after 12 months, 17.0%. During the observation, OKZ treatment was discontinued in 148 (9.5%) patients: in 50 (3.2%) patients due to insufficient efficacy, in 63 (4.0%) patients due to adverse events, and in 35 (2.2%) patients due to other reasons. Conclusion. IL-6 inhibition with OKZ is both effective and safe for achieving RA therapy goals in real-world clinical settings.https://mrj.ima-press.net/mrj/article/view/1738rheumatoid arthritisolokizumabil-6 inhibitorreal world evidence |
| spellingShingle | P. A. Shesternya A. I. Zagrebneva O. V. Antipova Yu. V. Arbuzova I. G. Bannikova L. V. Belozertseva E. A. Bogdanova S. A. Bykova E. A. Vasilenko I. B. Vinogradova S. Yu. Davidyan O. E. Epifanova E. V. Zemerova M. V. Zlobin L. V. Ivanova N. A. Ilyina L. V. Ilyushina E. P. Klyuchnikova A. V. Makevnina E. R. Myasoutova E. E. Nakonechnaya A. B. Pavlova T. V. Plaksina A. V. Rybin T. S. Salnikova L. V. Solodovnikova A. V. Fedorova I. A. Cherencova E. V. Jakovleva S. P. Yakupova E. N. Alekseev A. M. Lila Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence Современная ревматология rheumatoid arthritis olokizumab il-6 inhibitor real world evidence |
| title | Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence |
| title_full | Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence |
| title_fullStr | Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence |
| title_full_unstemmed | Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence |
| title_short | Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence |
| title_sort | use of olokizumab a direct interleukin 6 inhibitor in the treatment of rheumatoid arthritis real world evidence |
| topic | rheumatoid arthritis olokizumab il-6 inhibitor real world evidence |
| url | https://mrj.ima-press.net/mrj/article/view/1738 |
| work_keys_str_mv | AT pashesternya useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT aizagrebneva useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT ovantipova useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT yuvarbuzova useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT igbannikova useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT lvbelozertseva useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT eabogdanova useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT sabykova useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT eavasilenko useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT ibvinogradova useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT syudavidyan useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT oeepifanova useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT evzemerova useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT mvzlobin useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT lvivanova useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT nailyina useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT lvilyushina useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT epklyuchnikova useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT avmakevnina useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT ermyasoutova useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT eenakonechnaya useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT abpavlova useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT tvplaksina useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT avrybin useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT tssalnikova useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT lvsolodovnikova useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT avfedorova useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT iacherencova useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT evjakovleva useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT spyakupova useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT enalekseev useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence AT amlila useofolokizumabadirectinterleukin6inhibitorinthetreatmentofrheumatoidarthritisrealworldevidence |